The ROC analysis demonstrated that the nomogram model could accurately distinguish between patients who would benefit from ICIs than cancer type, TMB, treatment type, and PTPRD/PTPRT mutations (area under the curve [AUC] of 1-year survival, 0.612; AUC of 3-year survival, 0.649; AUC of 5-year survival, 0.618). This evidence concerns the gene PTPRT and cancer.